Testing lab-grown brain tumor and blood vessel models from surgery samples
Tests whether lab-grown models from surgery samples can be made in adults with glioblastoma.
Plain-language title generated from the registry record
Registry title: Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.
Key facts
- Where
- Le Havre and Rouen, FranceSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who may have a high-grade brain tumour (glioblastoma) and need surgery to remove it. Tumour and blood vessel samples from surgery are grown in the lab as organoids.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Suspected high-grade glioma on MRI before surgery, with surgery planned to remove the tumour. The summary describes newly diagnosed glioblastoma.
Main reasons for not taking part
- Current tumour disease, or a past tumour that has been in remission for less than 2 years
- Pregnant or breastfeeding women
- People who cannot understand the study or cannot follow the trial requirements
Read by machine on 12 November 2026.
Where in France
- Groupe Hospitalier du HavreLe Havre, FranceContact: Marine LacaudNo longer taking part
- Centre Henri BecquerelRouen, FranceContact: Maxime FontanillesNo longer taking part
- CHU RouenRouen, FranceContact: Olivier LangloisNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Henri Becquerel
- Trial code
- NCT07029100
- Record updated
- 19 June 2025
- Original description
The main goal of ORGA-GLIO trial is to establish the feasibility in routine clinical practice of ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and peri-tumoral blood vessels (blood vessel organoid - BVO), derived from perioperative samples obtained during complete or partial surgical resection in patients with newly diagnosed glioblastoma.Read full original descriptionShow less
Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.
The main goal of ORGA-GLIO trial is to establish the feasibility in routine clinical practice of ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and peri-tumoral blood vessels (blood vessel organoid - BVO), derived from perioperative samples obtained during complete or partial surgical resection in patients with newly diagnosed glioblastoma.
Inclusion: Patient, male or female, adult (age ≥ 18 years),; Suspected of having a high-grade glioma based on preoperative multimodal MRI,; With an indication for tumor resection surgery,; And in a clinical condition suitable to undergo adjuvant treatment consisting of radiotherapy (normo- or hypo-fractionated) combined with temozolomide, with or without low-frequency electric fields (Tumor-Treating Fields®).
Exclusion: Current tumor pathology or history of tumor pathology in remission for less than 2 years; Pregnant or breastfeeding women,; Patients unable to understand the study for any reason or unable to comply with trial requirements (language barriers, psychological or geographical issues, etc.).